← Coach hub · Coach Signals · Coach Brain · Sage Serotonin

Coach — Serotonin (Bioenergetic Flux Manager)

Not a happiness molecule. A whole-body manager of oxygen, fuel, and spending, so that expensive tissue does not bankrupt the energy budget.

Serotonin is not a happiness molecule. The sentence is short enough to be dismissed as contrarian branding. It is not. It is the framing that best survives contact with the molecule's actual distribution, evolutionary history, and pharmacology.

Most of the body's serotonin is in the gut. Most of what remains in the circulation is packed into platelets. The molecule was first isolated as enteramine, an amine of the intestine, and then renamed serotonin because it was a serum factor that changed vascular tone. Neither name points at mood. Both point at the coordination of flow: moving the contents of the gut, setting the tone of vessels, partitioning blood, timing oxygen delivery. The later claim that serotonin is a "happy chemical" was not a discovery. In the report's reading, it grew up alongside a class of drugs whose main action is to block the serotonin transporter, the protein that pulls serotonin back into cells.

Serotonergic medicines have real clinical value for selected people. Some get better. Some get worse. Many get a delayed, incomplete, state-dependent change that does not look like the replacement of a missing chemical. The mood-chemical story is incomplete in the way a purely genetic story of cancer is incomplete. It describes a dashboard reading and a useful lever. It does not describe the engine.

Two incomplete stories

The deficiency story says depression is low serotonin at the synapse: block the transporter, raise serotonin, restore mood, and treat the two-to-six-week delay as a black box. A 2022 umbrella review in Molecular Psychiatry, by Moncrieff and colleagues, found no consistent evidence that depression is associated with lowered serotonin concentration or activity. Meanwhile, an SSRI occupies the transporter throughout the body within hours, yet its antidepressant effects, when they come, take weeks. If the problem were a missing drop at the synapse, that mismatch would be surprising.

The brain-first story fails on geography. A brain-first happiness chemical should not be stored mainly in gut cells and platelets. It should not be the starting material for melatonin made inside mitochondria. It should not constrict poorly ventilated patches of lung, drive the gut's contractions after a meal, or drain out of platelets when the transporter is blocked. Those facts are not side quests. They are the main plot.

In 2015 Paul Andrews and colleagues stated a cleaner paradox: serotonin transmission appears elevated in several depressive states, SSRIs raise it further and often worsen symptoms at first, and later improvement is better read as the brain's attempt to restore its energy balance after that disturbance. Their energy-regulation idea is the closest published ancestor of this one. The hypothesis here pushes one layer deeper, from how energy is allocated among organs to how it is generated at the mitochondrion, with oxygen as the rate-limiting partner.

Upstream: flow

Multicellular life is an energy problem. Food electrons move down the mitochondrial energy chain, protons are pumped, and oxygen is the final acceptor. When oxygen, fuel, cofactors, or the machinery fall short of load, cells shift toward faster, less efficient energy production, change how blood and behavior are allocated, and broadcast stress signals.

On this reading, serotonin is a whole-body manager of that flow. Its evolved job is to coordinate the supply, storage, and use of oxygen and fuel so that mitochondrial energy production matches local and systemic demand. When supply is threatened, serotonin may rise or be redistributed as a short-term signal. When the mismatch becomes chronic, the same signal can lock the body into a compensatory mode later given many names: depression, anxiety, fatigue, gut dysmotility, pulmonary hypertension, platelet problems, withdrawal, "brain zaps." The molecule can look like a vessel constrictor in one place, a gut hormone in another, a brake on brown-fat heat in a third, and a synaptic modulator in a fourth, because those are local answers to one question: where should scarce energy capacity go right now?

Chris Masterjohn's metaphor helps if kept precise: serotonin as the mitochondrion's firefighter, melatonin as its guardian. The body's own melatonin, made from the same tryptophan backbone inside mitochondria, is the standing night watch. Serotonin is an emergency and load-matching signal, not a tonic that should bathe the system all day.

Three rooms, one manager

The gut is the first oxygen-hungry reactor of every meal. Eating raises the metabolic rate of the gut lining, local oxygen falls, serotonin release rises, and contractions move food along so it does not stall. Nausea or gut changes in the first days on a transporter-blocking drug are, in this map, the valve being turned where serotonin already works hardest.

Platelets do not make serotonin. They harvest it through the transporter and store it, a circulating reserve released where vessels and clotting need attention. Block the transporter chronically and that reserve empties. Untreated depression does not produce the same drop; it is a drug effect, not a signature of depression. Aspirin is a useful contrast: it reduces serotonin release during clotting without emptying platelet stores, and nobody mistakes it for an antidepressant.

The brain is expensive tissue with high energy demand and little tolerance for gaps in supply. Sustained rumination is metabolically costly, and elevated serotonin tone in melancholic states can be read as reallocation, not a failed attempt at happiness. Effects depend on the body's state: raising serotonin in a well-fed, well-slept person with spare mitochondrial capacity is a different intervention from raising it in someone sleep-deprived, inflamed, and insulin-resistant. Weight gain and metabolic flattening on SSRIs fit the same frame: storage decisions made with a jammed valve, including brown fat losing protection against serotonin's brake on heat production.

What the timeline shows, and why this is not a taper plan

The timeline of transporter occupancy is the hypothesis's sharpest test, described here as education and never as a taper plan. In hours to days, occupancy is high, the platelet reserve begins to fall, the gut reacts, sleep changes, and anxiety or flattening can rise. Over weeks, receptors and gene expression adapt; improvement that depends on a jammed valve staying jammed is the shape of a compensatory lock. Over months, a system built for intermittent matching loses range under constant occupancy: sexual function, an expensive optional program, is among the first to be cut, and emotional blunting is reduced spending on costly feeling. Withdrawal is an abrupt change in the valve while the reserve is still depleted and the adaptations still belong to the jammed state: dizziness, electric-shock sensations, instability, rebound anxiety. Urgent or destabilizing symptoms belong with your physician or emergency care. No discontinuation schedule appears here, and any change to these medicines is a decision to make with the physician who prescribes them.

None of this denies that some people need and benefit from these drugs. It asks for honesty about what they do: not serotonin replacement but, in this hypothesis, chronic occupancy of a whole-body valve, with delayed remodeling and a withdrawal physiology that looks like engine instability.

The methylene blue neighborhood

One more molecule needs a loud warning. Methylene blue is discussed on this site as a tool that can carry electrons around bottlenecks in the energy chain. It is also a potent, reversible inhibitor of MAO-A, the enzyme on the outer mitochondrial membrane that breaks serotonin down. Picture the transporter as a valve and MAO-A as shears. Methylene blue, serotonergic drugs, psychedelics, and metabolic interventions can cause serious harm, including serotonin toxicity, hemolysis in G6PD deficiency, withdrawal syndromes, and pregnancy-related risk.

The methylene blue essay discusses a low, intermittent amount it calls Window A, as information, never a recommendation, with any use physician-guided. Methylene blue at the Window A amount discussed in EnSurf, MAO inhibitors, high-dose tryptophan or 5-HTP, and SSRIs are not interchangeable wellness accessories. Intermittent MB is still a MAOI on dosing days. You still do not occupy that neighborhood casually, and you do not stack it with SERT drugs. Do not combine with serotonergic drugs. Do not use in G6PD deficiency.

That is why stacking MB with SSRIs, SNRIs, MAOIs, tramadol, triptans, or high-dose 5-HTP is a hard stop. You do not occupy the shears and the valve at the same time. SRI, SNRI, MAOI, tramadol, triptan, 5-HTP, and psychedelic stacking remains a hard stop on dosing days and through washout. Reversible does not mean "safe with sertraline if you only dose twice a week." Do not combine with SERT or MAO drugs, 5-HTP, or a psychedelic pulse. Washout exists for a reason. Combined with SERT block: no packaging into platelets, no synaptic clearance, no MAO disposal. The buffer, the valve, and the shears are all offline. That is serotonin toxicity, not hormesis. If someone feels "serotonergic" on a dosing day—jaw tightness, clonus, agitation, sweating, diarrhea, insomnia—that is the shears, not the wire. Stop. Do not start, stop, combine, or taper medications or supplements—including SSRIs, SNRIs, MAOIs, 5-HTP, psychedelics, or methylene blue—on the basis of this essay. Serotonin toxicity, G6PD-related hemolysis, and drug–drug interactions are real.

Why the signal misbehaves now

The body was tuned for intermittent food, solar light, obligatory movement, and real seasons. Daylight, movement, and meals should raise and lower serotonin tone; night should turn the same tryptophan backbone into the body's own mitochondrial melatonin. Modern life keeps the firefighter in a smoky building: continuous insulin-raising food, indoor light and late sleep that collapse the handoff from serotonin to melatonin, inactivity that removes the signals for building mitochondria, and chronic inflammation that diverts tryptophan elsewhere.

In this hypothesis, depression in this setting is often the experience of an organism whose engine cannot cover its cognitive and social bills. That experience is real; in this philosophy, experience is the ground floor, not a by-product and not a second substance. Sometimes interrupting the compensatory state with a drug is worth it. Often the more coherent move is to restore what the manager evolved to serve: food the mitochondria were built on, morning light and dark nights, strength and aerobic work, sleep, and treated sleep apnea, since oxygen is the final acceptor.

Order, not anti-psychiatry

Do not start, stop, combine, or taper antidepressants, serotonergic drugs, psychedelics, or methylene blue from this page. Serotonin toxicity, G6PD-related hemolysis risk with methylene blue, withdrawal syndromes, pregnancy-related risk, and psychiatric emergencies belong in urgent clinical care. Acute risk comes first: suicidal thoughts, psychosis, mania, serotonin toxicity, and medical emergencies belong with physicians and emergency care, and nothing here competes with that. The daily basics come next: the Fuel essay and its stings, the circadian day, and strength. Psychiatric medicines stay with the physician who prescribes them. This essay reframes questions for a better conversation; it does not replace prescribing judgment, offer taper charts, or shame anyone for taking medication. Anti-psychiatry and medication-only thinking are twin errors.

Mood scores, sleep trackers, and platelet trivia can move when the weather changes. They do not authorize anyone to invent a diagnosis or a taper from an essay. The discipline is to keep psychiatry in the chair while the daily foundations are repaired, and to refuse to let a transporter slogan become the whole story of mood. For the long argument, read the extended report on serotonin, and the related essays on signals and the brain.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 31, 2026.

Sage — Serotonin · Signals · Brain · Methylene Blue · Fuel toxins · Circadian